Mississauga — GenomeArc today announced the release of Horizon Platform version 2.3.0, its most comprehensive and advanced version to date, delivering a major leap forward in clinical genetics solutions for rare diseases and oncology. 

Horizon v2.3.0 introduces a fully integrated suite of capabilities designed to accelerate diagnostic interpretation, improve clinical confidence, and support precision medicine at scale. The release reflects GenomeArc’s continued commitment to bridging complex genomic data with actionable clinical insight. 

Horizon v2.3.0 delivers a fully integrated and significantly expanded platform designed to accelerate diagnostic interpretation, strengthen clinical confidence, and enable precision medicine at scale. This release underscores GenomeArc’s commitment to transforming complex genomic data into actionable clinical insight, featuring AMP-guided variant tiering aligned with AMP/ASCO/CAP standards and enriched with approved or well researched therapeutic insights, advanced tumor variant intelligence covering mutation burden, clonal architecture, and tumor complexity, an expanded proprietary database of over 30,000 clinically relevant rare disease variants, and an AI-powered agent that streamlines variant search and interpretation for faster, more intuitive clinical decision-making. 

“With Horizon 2.3.0, we are delivering the most complete version of the platform we have built so far,” said Mohammed Dafil, Founder and CEO of GenomeArc. “This release brings together ultra-fast computation, multi-modal omics analysis, and clinically guided interpretation to support both rare disease diagnosis and oncology decision-making with unprecedented depth and efficiency.” 

Designed for clinical geneticists, molecular pathologists, and translational researchers, Horizon Platform v2.3.0 enables users to move seamlessly from raw genomic data to actionable diagnostic and therapeutic insights, reducing interpretation bottlenecks while maintaining clinical rigor. 

The platform’s enhanced oncology module strengthens GenomeArc’s position in precision oncology by directly supporting tumor stratification, therapy selection, and variant prioritization, while the expanded rare disease knowledge base improves diagnostic yield in complex and unresolved cases. 

Horizon Platform v2.3.0 is now available to GenomeArc clients worldwide.